2月26日,国家药品监督管理局药品审评中心(CDE)官网显示,三生国建自主研发的重组抗IL-4Rα人源化单克隆抗体注射液(研发代码:SSGJ-611)上市申请获受理,用于治疗外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎(AD)。特应性皮炎(Atopic Dermatitis, AD)是一种慢性、复发性、炎症性皮肤病。中重度特应性皮炎患者通常全身大部位皮肤红疹,引发强烈持续的瘙痒、皮肤干燥...
Source Link2月26日,国家药品监督管理局药品审评中心(CDE)官网显示,三生国建自主研发的重组抗IL-4Rα人源化单克隆抗体注射液(研发代码:SSGJ-611)上市申请获受理,用于治疗外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎(AD)。特应性皮炎(Atopic Dermatitis, AD)是一种慢性、复发性、炎症性皮肤病。中重度特应性皮炎患者通常全身大部位皮肤红疹,引发强烈持续的瘙痒、皮肤干燥...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.